Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 917.75
NLNK's Cash-to-Debt is ranked higher than
55% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NLNK: 917.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NLNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79  Med: 62.74 Max: 917.75
Current: 917.75
0.79
917.75
Equity-to-Asset 0.88
NLNK's Equity-to-Asset is ranked higher than
75% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NLNK: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
NLNK' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.81 Max: 0.93
Current: 0.88
-5.11
0.93
Piotroski F-Score: 3
Altman Z-Score: -0.38
WACC vs ROIC
10.77%
762.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -293.00
NLNK's Operating Margin % is ranked lower than
60% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NLNK: -293.00 )
Ranked among companies with meaningful Operating Margin % only.
NLNK' s Operating Margin % Range Over the Past 10 Years
Min: -2849.13  Med: -883.12 Max: 68.12
Current: -293
-2849.13
68.12
Net Margin % -253.52
NLNK's Net Margin % is ranked lower than
60% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NLNK: -253.52 )
Ranked among companies with meaningful Net Margin % only.
NLNK' s Net Margin % Range Over the Past 10 Years
Min: -2852.7  Med: -873.02 Max: 55.63
Current: -253.52
-2852.7
55.63
ROE % -44.09
NLNK's ROE % is ranked lower than
58% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NLNK: -44.09 )
Ranked among companies with meaningful ROE % only.
NLNK' s ROE % Range Over the Past 10 Years
Min: -85.27  Med: -51.79 Max: 75.23
Current: -44.09
-85.27
75.23
ROA % -36.69
NLNK's ROA % is ranked lower than
59% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NLNK: -36.69 )
Ranked among companies with meaningful ROA % only.
NLNK' s ROA % Range Over the Past 10 Years
Min: -86.63  Med: -56.39 Max: 63.63
Current: -36.69
-86.63
63.63
ROC (Joel Greenblatt) % -1339.95
NLNK's ROC (Joel Greenblatt) % is ranked lower than
63% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NLNK: -1339.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NLNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1339.95  Med: -424.2 Max: 1658.8
Current: -1339.95
-1339.95
1658.8
3-Year Revenue Growth Rate -45.20
NLNK's 3-Year Revenue Growth Rate is ranked lower than
82% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. NLNK: -45.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NLNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -45.2  Med: 91.5 Max: 209.3
Current: -45.2
-45.2
209.3
GuruFocus has detected 2 Warning Signs with NewLink Genetics Corp NLNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NLNK's 30-Y Financials

Financials (Next Earnings Date: 2019-02-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

NLNK Guru Trades in Q3 2017

Steven Cohen 178,680 sh (New)
Louis Moore Bacon 50,000 sh (New)
Paul Tudor Jones 40,714 sh (+4.62%)
First Eagle Investment 2,494,200 sh (+2.05%)
First Eagle Investment 2,278 sh (unchged)
Jim Simons Sold Out
» More
Q4 2017

NLNK Guru Trades in Q4 2017

Pioneer Investments 202,200 sh (New)
Louis Moore Bacon 100,000 sh (+100.00%)
First Eagle Investment 2,644,700 sh (+6.03%)
First Eagle Investment 2,278 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2018

NLNK Guru Trades in Q1 2018

Jim Simons 179,432 sh (New)
Louis Moore Bacon Sold Out
First Eagle Investment 2,346,300 sh (-11.28%)
Pioneer Investments 136,012 sh (-32.73%)
» More
Q2 2018

NLNK Guru Trades in Q2 2018

Jim Simons 405,100 sh (+125.77%)
Pioneer Investments Sold Out
First Eagle Investment 759,250 sh (-67.64%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SPRO, NAS:IMDZ, XKRX:222110, TSE:2385, NAS:SLGL, XKLS:7090, LSE:TRX, NAS:XBIT, NAS:SCPH, TSE:4596, NAS:FOMX, XTER:PA8, NAS:MRNS, TSX:RVX, XKRX:002630, NAS:PTI, OSL:PCIB, XTAE:NTEC, XAMS:KDS, NAS:MNLO » details
Traded in other countries:4NX.Germany,
Headquarter Location:USA
NewLink Genetics Corp is a clinical stage immuno-oncology company based in US. It focuses on developing novel immunotherapeutic products for the treatment of cancer. Its portfolio contains biologic and small-molecule immuno-oncology product candidates.

NewLink Genetics Corp is an American biotechnology company targeting immunotherapeutic products to improve treatment options for patients with cancer. The company's portfolio contains biologic and small-molecule immuno-oncology product candidates intended to treat a wide variety of oncology indications. Its products are based on the proprietary HyperAcute Cellular Immunotherapy technology, which is expected to stimulate the human immune system.

Top Ranked Articles about NewLink Genetics Corp

NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
NewLink Genetics Presents Phase 1 Data Supporting Significantly Higher Exposure with Indoximod Prodrug, NLG802, and Biomarker Data from Two Phase 2 Trials Illustrating Indoximod’s Impact on the Tumor Microenvironment at SITC 2018
NewLink Genetics Announces Publication of Abstracts for Presentation at the Society for Immunotherapy for Cancer (SITC) Conference
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
CORRECTED: NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings
NewLink Genetics Announces Oral Presentation at the 2018 American Society of Hematology (ASH) Annual Meeting
NewLink Genetics to Participate in the Stifel 2018 Healthcare Conference
NewLink Genetics to Host Its Third Quarter 2018 Financial Results Conference Call on November 1, 2018
NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018

Ratios

vs
industry
vs
history
PB Ratio 0.60
NLNK's PB Ratio is ranked higher than
93% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. NLNK: 0.60 )
Ranked among companies with meaningful PB Ratio only.
NLNK' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 5.3 Max: 21.18
Current: 0.6
0.58
21.18
PS Ratio 3.05
NLNK's PS Ratio is ranked higher than
77% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NLNK: 3.05 )
Ranked among companies with meaningful PS Ratio only.
NLNK' s PS Ratio Range Over the Past 10 Years
Min: 2.98  Med: 14.34 Max: 1081.4
Current: 3.05
2.98
1081.4
EV-to-EBIT 0.80
NLNK's EV-to-EBIT is ranked higher than
94% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. NLNK: 0.80 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.9  Med: -4.9 Max: 13.5
Current: 0.8
-36.9
13.5
EV-to-EBITDA 0.80
NLNK's EV-to-EBITDA is ranked higher than
95% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. NLNK: 0.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
NLNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38  Med: -5.1 Max: 13.4
Current: 0.8
-38
13.4
EV-to-Revenue -2.39
NLNK's EV-to-Revenue is ranked lower than
99.99% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. NLNK: -2.39 )
Ranked among companies with meaningful EV-to-Revenue only.
NLNK' s EV-to-Revenue Range Over the Past 10 Years
Min: -2.2  Med: 9.6 Max: 1046.8
Current: -2.39
-2.2
1046.8
Current Ratio 13.33
NLNK's Current Ratio is ranked higher than
73% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. NLNK: 13.33 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 8.94 Max: 25.95
Current: 13.33
0.97
25.95
Quick Ratio 13.33
NLNK's Quick Ratio is ranked higher than
74% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. NLNK: 13.33 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 8.94 Max: 25.95
Current: 13.33
0.97
25.95

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.90
NLNK's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. NLNK: -9.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NLNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.7  Med: -11.1 Max: -3.1
Current: -9.9
-22.7
-3.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.67
NLNK's Price-to-Net-Cash is ranked higher than
96% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. NLNK: 0.67 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NLNK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.65  Med: 6.45 Max: 29.76
Current: 0.67
0.65
29.76
Price-to-Net-Current-Asset-Value 0.59
NLNK's Price-to-Net-Current-Asset-Value is ranked higher than
96% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. NLNK: 0.59 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NLNK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.58  Med: 5.84 Max: 21.93
Current: 0.59
0.58
21.93
Price-to-Tangible-Book 0.57
NLNK's Price-to-Tangible-Book is ranked higher than
96% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. NLNK: 0.57 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NLNK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.56  Med: 5.49 Max: 14.64
Current: 0.57
0.56
14.64
Price-to-Median-PS-Value 0.22
NLNK's Price-to-Median-PS-Value is ranked higher than
89% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. NLNK: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NLNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.09 Max: 47.33
Current: 0.22
0.21
47.33
Earnings Yield (Greenblatt) % 122.41
NLNK's Earnings Yield (Greenblatt) % is ranked higher than
99% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. NLNK: 122.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NLNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -871.3  Med: -8.8 Max: 643.3
Current: 122.41
-871.3
643.3

More Statistics

Revenue (TTM) (Mil) $22.37
EPS (TTM) $ -1.48
Beta1.24
Volatility47.86%
52-Week Range $1.83 - 10.41
Shares Outstanding (Mil)37.22

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.98 -1.42
EPS without NRI ($) -1.98 -1.42
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}